[go: up one dir, main page]

DE60020351D1 - Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen - Google Patents

Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen

Info

Publication number
DE60020351D1
DE60020351D1 DE60020351T DE60020351T DE60020351D1 DE 60020351 D1 DE60020351 D1 DE 60020351D1 DE 60020351 T DE60020351 T DE 60020351T DE 60020351 T DE60020351 T DE 60020351T DE 60020351 D1 DE60020351 D1 DE 60020351D1
Authority
DE
Germany
Prior art keywords
infections
azalid
occular
antibiotics
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60020351T
Other languages
English (en)
Other versions
DE60020351T2 (de
Inventor
R Dawson
M Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26961283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60020351(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Application granted granted Critical
Publication of DE60020351D1 publication Critical patent/DE60020351D1/de
Publication of DE60020351T2 publication Critical patent/DE60020351T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60020351T 1999-03-31 2000-03-27 Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen Expired - Lifetime DE60020351T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28216599A 1999-03-31 1999-03-31
US282165 1999-03-31
US346923 1999-07-02
US09/346,923 US6239113B1 (en) 1999-03-31 1999-07-02 Topical treatment or prevention of ocular infections
PCT/US2000/007924 WO2000057866A2 (en) 1999-03-31 2000-03-27 Use of azalide antibiotics for the topical treatment or prevention of ocular infections

Publications (2)

Publication Number Publication Date
DE60020351D1 true DE60020351D1 (de) 2005-06-30
DE60020351T2 DE60020351T2 (de) 2006-01-26

Family

ID=26961283

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60020351T Expired - Lifetime DE60020351T2 (de) 1999-03-31 2000-03-27 Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
DE1165058T Pending DE1165058T1 (de) 1999-03-31 2000-03-27 Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1165058T Pending DE1165058T1 (de) 1999-03-31 2000-03-27 Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen

Country Status (15)

Country Link
US (5) US6239113B1 (de)
EP (2) EP1165058B1 (de)
JP (1) JP4904621B2 (de)
KR (1) KR100701721B1 (de)
AT (1) ATE296093T1 (de)
AU (1) AU772228B2 (de)
CA (1) CA2368637C (de)
CY (1) CY1107259T1 (de)
DE (2) DE60020351T2 (de)
DK (1) DK1165058T3 (de)
ES (1) ES2244421T3 (de)
HK (1) HK1041642B (de)
MX (1) MXPA01009718A (de)
PT (1) PT1165058E (de)
WO (1) WO2000057866A2 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) * 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6699492B2 (en) 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
JP3502574B2 (ja) 1999-06-29 2004-03-02 東亜薬品株式会社 眼感染症治療用眼軟膏剤
NZ517706A (en) * 1999-10-08 2004-01-30 Affinium Pharm Inc Fab I inhibitors
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6914051B1 (en) * 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
WO2002007736A1 (en) * 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
DE60230934D1 (de) * 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
CA2445606A1 (en) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Taste masking pharmaceutical composition
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
EP1446010B1 (de) * 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Stabilisierte azithromycin-zusammensetzungen
WO2003041500A1 (en) * 2001-11-14 2003-05-22 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
JPWO2003072589A1 (ja) * 2002-02-26 2005-06-16 明治製菓株式会社 新規１５員環アザライド及び新規１６員環ジアザライド誘導体とその製造法
CN1313155C (zh) * 2002-03-18 2007-05-02 诺瓦提斯公司 包含环果聚糖、载体和药物的局部用组合物
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
ES2518316T3 (es) * 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
ATE409485T1 (de) 2003-03-17 2008-10-15 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7125497B1 (en) * 2003-05-22 2006-10-24 Sandia Corporation Reactive formulations for a neutralization of toxic industrial chemicals
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
WO2006004085A1 (ja) 2004-07-02 2006-01-12 Wakamoto Pharmaceutical Co., Ltd. アジスロマイシン含有水性医薬組成物及びその調製方法
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20080227730A1 (en) * 2005-01-14 2008-09-18 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB2438544A (en) * 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
WO2006102378A2 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
FR2884716B1 (fr) * 2005-04-22 2009-08-21 Thea Sa Lab Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires
CN100393738C (zh) * 2005-07-05 2008-06-11 广州市微生物研究所 纳他霉素的提取纯化方法
EP1904056B1 (de) 2005-07-18 2009-04-29 Minu, L.L.C. Verwendung von Makroliden zur Wiederherstellung der Kornealempfindungen
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
EP1973902A2 (de) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
EP3838903B1 (de) 2005-12-13 2023-11-22 Incyte Holdings Corporation Pyrrolo[2,3-b]pyrimidinderivat als janus-kinase-inhibitoren
JPWO2007074904A1 (ja) * 2005-12-28 2009-06-04 わかもと製薬株式会社 水性医薬組成物
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
AU2007230964B2 (en) * 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US7758553B2 (en) * 2006-04-03 2010-07-20 Insight Vision Incorporated Drop dispenser for the delivery of uniform droplets of viscous liquids
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
EP2687533B1 (de) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CN101932582B (zh) 2007-06-13 2013-09-25 因塞特公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
US8710019B2 (en) * 2007-07-25 2014-04-29 Ixodes Ag Topical antibiotic composition for the prevention of Lyme disease
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
ATE534390T1 (de) * 2007-11-19 2011-12-15 Bausch & Lomb Verwendung von levocabastin zur modulierung der erzeugung von proinflammatorischen zytokinen
EP2098219A1 (de) 2008-03-05 2009-09-09 PARI Pharma GmbH Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US9006210B2 (en) * 2008-06-13 2015-04-14 Case Western Reserve University Compositions and methods for treating corneal inflammation
EP2310008A4 (de) * 2008-07-09 2014-03-05 Aspreva Internat Ltd Ph-spezifische lösungen aus natriummycophenolsäure zur behandlung von augenleiden
MX2011000247A (es) * 2008-07-10 2011-03-30 Inspire Pharmaceuticals Inc Composicion farmaceutica para el tratamiento de blefaritis.
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
US20100190734A1 (en) * 2009-01-23 2010-07-29 Romulus Kimbro Brazzell Method of treating dry eye disease with azithromycin
US10980818B2 (en) * 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US20170128481A9 (en) * 2009-03-06 2017-05-11 Insite Vision Corporation Ocular treatment with reduced intraocular pressure
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
CA2760932A1 (en) * 2009-05-04 2010-11-11 Thierry Nivaggioli Mtor pathway inhibitors for treating ocular disorders
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
RS59632B1 (sr) 2009-05-22 2020-01-31 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
US8716303B2 (en) * 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
ME02386B (de) 2010-03-10 2016-09-20 Incyte Holdings Corp Piperidin-4-yl azetidinderivate als jak1-inhibitoren
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
USD640554S1 (en) 2010-06-30 2011-06-28 Inspire Pharmaceuticals, Inc. Medicine dispenser
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
ES2623233T3 (es) 2011-05-25 2017-07-10 Novaliq Gmbh Composición farmacéutica tópica a base de alcanos semifluorados
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
JP2014518275A (ja) * 2011-06-29 2014-07-28 インサイト・ビジョン・インコーポレイテッド 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法
CN102352058B (zh) * 2011-08-04 2013-04-24 华南农业大学 稳定水溶性纤维素水凝胶粘度的复合添加剂及应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013065029A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
JP6084987B2 (ja) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー セミフッ素化アルカンに基づく安定化タンパク質組成物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
RS58898B1 (sr) 2012-06-19 2019-08-30 Debiopharm Int Sa Prolek derivati (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
KR20140009819A (ko) * 2012-07-13 2014-01-23 주식회사유한양행 반코마이신 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
EP3100722B1 (de) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorierte alkane zur solubilisierung von meibum
US9770508B2 (en) 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
DK2964650T3 (en) 2013-03-06 2019-02-11 Incyte Holdings Corp PROCEDURES AND INTERMEDIATES FOR THE MANUFACTURE OF A JAK INHIBITOR
EP3520773A1 (de) 2013-03-14 2019-08-07 PanOptica, Inc. Augenformulierungen für wirkstofffreisetzung im hinteren segment des auges
US9044508B2 (en) * 2013-03-15 2015-06-02 Insite Vision Corporation Concentrated aqueous azalide formulations
WO2014160579A1 (en) * 2013-03-25 2014-10-02 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
SI3030227T1 (sl) 2013-08-07 2020-08-31 Incyte Corporation Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
EA201690323A1 (ru) 2013-08-27 2016-07-29 Отономи, Инк. Способы лечения заболеваний уха у детей
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6200108B2 (ja) 2014-06-20 2017-09-20 クーパーヴィジョン インターナショナル ホウルディング カンパニー リミテッド パートナーシップ 眼感染症の治療のための眼科用組成物
US9241971B1 (en) 2014-07-18 2016-01-26 Kurobe, Llc Topical vancomycin formulation and methods of use
RU2580631C1 (ru) * 2015-03-19 2016-04-10 Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита" Антибактериальное лекарственное средство в форме мази для лечения глазных болезней у животных
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
ES2953837T3 (es) 2015-09-30 2023-11-16 Novaliq Gmbh 2-perfluorobutil pentano para administración oftálmica
RU2610408C1 (ru) * 2016-01-11 2017-02-09 Акционерное общество "Екатеринбургский центр МНТК "Микрохирургия глаза" Способ лечения острых бактериальных послеоперационных эндофтальмитов
PT3419628T (pt) 2016-02-26 2021-01-05 Debiopharm Int Sa Medicamento para o tratamento de infeções do pé diabético
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
EP3500254B1 (de) 2016-08-16 2022-03-23 University of Rochester Pharmazeutische zusammensetzung mit therapeutika auf der basis von polymixin b/trimethoprim
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
EP3515467B1 (de) 2016-09-23 2023-11-29 Novaliq GmbH Ophthalmische zusammensetzungen mit ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
US10940163B2 (en) 2017-02-02 2021-03-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
CN110650734B (zh) 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
WO2018213389A1 (en) * 2017-05-17 2018-11-22 Nextcea Inc. Inducing phospholipidosis for enhancing therapeutic efficacy
WO2018215638A1 (en) 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
MY206999A (en) 2018-03-30 2025-01-23 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
WO2020024060A1 (en) 2018-08-01 2020-02-06 Mcmaster University Methods for inhibiting microbe growth
CN113164043B (zh) * 2018-09-21 2024-10-22 奥夫博医疗创新有限公司 用于青光眼的组合物和方法
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CA3129508A1 (en) 2019-02-14 2020-08-20 Debiopharm International S.A. Solid formulations of afabicin with histidine
EP3955926A4 (de) 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. Verbindungen und zusammensetzungen zur behandlung von augenkrankheiten
KR20210154214A (ko) 2019-04-18 2021-12-20 아주라 오프탈믹스 엘티디 안구 질병의 치료를 위한 화합물 및 방법
JP7696697B2 (ja) * 2019-06-13 2025-06-23 千寿製薬株式会社 アジスロマイシン含有眼科用剤
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021381495A1 (en) 2020-11-23 2023-06-22 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2024216070A1 (en) 2023-04-14 2024-10-17 University Of Rochester Combinatorial pharmaceutical compositions for treatment of bacterial infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
ES532317A0 (es) 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
US4551456A (en) 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4692454A (en) 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5807830A (en) 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
YU45590A (sh) 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
US5912331A (en) 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5225399A (en) 1991-04-15 1993-07-06 The Children's Hospital Of Philadelphia Antimicrobial amphiphilic peptides
US5239059A (en) 1991-05-10 1993-08-24 The Children's Hospital Of Philadelphia Ion-channel forming peptides
JP2880338B2 (ja) * 1991-10-25 1999-04-05 株式会社森組 圧搾気体による被移送物の圧送方式
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5424290A (en) 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
US5631004A (en) 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
EP0721324A1 (de) * 1993-10-01 1996-07-17 The Procter & Gamble Company Verwendung von azithromycin zur behandlung von paradontose bei erwachsenen und topische zubereitungen für die verwendung
ATE219684T1 (de) 1994-01-14 2002-07-15 Xoma Technology Ltd Anti gram positive bakterielle verfahren und mittel
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
HRP940251B1 (en) 1994-04-15 1998-12-31 Stjepan Mutak Process for the preparation of azithromycin dihydrochloride
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US6309630B1 (en) 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
AU4399396A (en) 1994-12-19 1996-07-10 Russinsky Limited Compounds
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
ATE287673T1 (de) 1995-06-07 2005-02-15 Southern Biosystems Inc Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
GB9621771D0 (en) 1996-10-18 1996-12-11 St George S Enterprises Ltd Method of treatment of heart disease
US5814655A (en) 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
PT102006B (pt) 1997-05-19 2000-06-30 Hovione Sociedade Quimica S A Novo processo de preparacao de azitromicina
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6159458A (en) 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
ES2221127T5 (es) 1997-12-02 2009-11-10 Pfizer Products Inc. Uso de acitromicina en el tratamiento topico de infecciones oculares.
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
AU2002317415A1 (en) 2001-08-01 2003-02-17 Pfizer Products Inc. Azalide antibiotic compositions

Also Published As

Publication number Publication date
MXPA01009718A (es) 2002-08-12
US7749970B2 (en) 2010-07-06
ATE296093T1 (de) 2005-06-15
JP2002540147A (ja) 2002-11-26
WO2000057866A3 (en) 2001-08-16
EP1165058A2 (de) 2002-01-02
DE1165058T1 (de) 2002-10-02
AU772228B2 (en) 2004-04-22
WO2000057866A2 (en) 2000-10-05
CY1107259T1 (el) 2012-11-21
DK1165058T3 (da) 2005-09-19
PT1165058E (pt) 2005-10-31
US20080161250A1 (en) 2008-07-03
CA2368637A1 (en) 2000-10-05
AU3920300A (en) 2000-10-16
US7732415B2 (en) 2010-06-08
CA2368637C (en) 2011-01-18
KR20020005634A (ko) 2002-01-17
US6239113B1 (en) 2001-05-29
KR100701721B1 (ko) 2007-03-29
HK1041642A1 (en) 2002-07-19
US6569443B1 (en) 2003-05-27
DE60020351T2 (de) 2006-01-26
US20030206956A1 (en) 2003-11-06
EP1165058B1 (de) 2005-05-25
JP4904621B2 (ja) 2012-03-28
US20040266702A1 (en) 2004-12-30
ES2244421T3 (es) 2005-12-16
HK1041642B (en) 2005-12-23
EP1588702A1 (de) 2005-10-26

Similar Documents

Publication Publication Date Title
DE60020351D1 (de) Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
ATE222126T1 (de) Minocyclin und edta enthaltende beschichtungszusammensetzung für medizinische geräte
FR11C0037I2 (fr) Antibiotiques macrolides et traitement de la pasteurellose
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
BR9510423A (pt) Formulação lipossomal multilamelar de baixa rigidez processo de tratamento ou de profilaxia de uma infecção bacteriana em um animal e de uma variante mucoìde da mesma, uso da formulação lipossomal antibacteriana
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
AR027234A1 (es) Derivados de la toxina clostridial y metodos para el tratamiento del dolor
BR0210941A (pt) Terapia de combinação de oxazolidinonas substituìdas
PE20001112A1 (es) Derivados de quinolina como agentes antibacterianos
MXPA03003168A (es) Composicion antibiotica topica para el tratamiento de infeccion de los ojos.
ATE348826T1 (de) Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
BRPI0009719B8 (pt) processo de tratamento
BR9711843A (pt) Uso de mupirocina para a fabricação de um medicamento para o tratamento de infecções bacterianas associadas com colonização da nasofaringe por organimos patogênicos
CA2254682A1 (en) Method of treating eye infections with azithromycin
ATE161265T1 (de) Derivate von 16-gliedrigen antibiotischen macroliden
PT90085A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um complexo organico de ouro para aplicacao topica
BR9912004A (pt) Oxazolidinonas para tratar infecções dos olhos
ATE337002T1 (de) Topische behandlung zur vorbeugung von augeninfektionen
ES2090167T3 (es) Uso topico de glicosaminoglicanos en la prevencion y el tratamiento de enfermedades que afectan al tracto vaginal cervical.
EP0389924A3 (de) Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen
CO5011042A1 (es) Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica
ES2196769T3 (es) Uso topico de loperamide para el tratamiento de infecciones microbianas.
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
AU2002331878A1 (en) Treating infections by administration of oxazolidinones to the skin
MX9204845A (es) Combinaciones de compuestos de cloruro de amonio ymetodo para el tratamiento de infecciones virales.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HOFFMANN & EITLE, 81925 MUENCHEN